- $504.78m
- -$62.82m
- $262.60m
Arvinas Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Arvinas - Pfizer, And Rigel Receive Hart-Scott-Rodino Clearance For License Agreement On June 11, 2026
Brief: Arvinas - Announces Re-Prioritization Of Portfolio Following Strategic Review - SEC Filing
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology
Rigel rises on licensing deal for Pfizer-Arvinas breast cancer drug
Rigel rises on licensing deal for Pfizer-Arvinas breast cancer drug
Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug
Arvinas Q1 sales miss estimates on lower collaboration revenue from Pfizer
Brief: Arvinas Q1 Operating Expenses USD 79.4 Million
Brief: Arvinas And Pfizer Enter Into A Transaction With Rigel Pharmaceuticals For The Exclusive Global Rights Of Veppanu
Brief: Arvinas Announces FDA Approval Of Veppanu For Treatment Of ESR1m, ER+/HER2- Advanced Breast Cancer
Arvinas rises after US FDA approves Pfizer, co's breast cancer drug
NASDAQ RESUMED AT 01:05 PM
US FDA approves Pfizer, Arvinas' breast cancer drug (updated)
US FDA approves Pfizer, Arvinas' breast cancer drug
NASDAQ TRADE HALT HALT NEWS PENDING AT 11:22 AM
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies
U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist